Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Matthew Meyerson, MD, PhD, co-senior author of the lung cancer study
Scientists today announced the results of the largest genomic study
to date of lung adenocarcinoma, the most common form of lung cancer.
Led by researchers from Dana-Farber Cancer Institute, the Broad
Institute of MIT and Harvard, and other research institutions
nationwide, the collaborative study unearthed a variety of genetic
alterations in patient tumors and pinpointed 26 frequently altered genes
— more than doubling the number already linked to the disease.
The work, which appears in the October 23 advance online edition of the journal Nature,
draws upon multiple large-scale approaches to highlight key molecular
defects in lung tumors that are often found in other forms of cancer, a
convergence that could open important avenues for treatment.
"In recent years, there's been some important successes for targeted
therapies for some types of lung cancer," said co-senior author Matthew Meyerson, MD, PhD, an associate professor at Dana-Farber Cancer
Institute and Harvard Medical School and a senior associate member of
the Broad Institute of MIT and Harvard. "This work helps identify new
targets that might show promise for treating broader groups of lung
Lung cancer exacts an overwhelming human toll. With over one million
deaths worldwide each year, it ranks as the primary cause of
cancer-related mortalities. As in the majority of cancers, lung
adenocarcinoma stems from abnormalities that accumulate in cells' DNA
over a person's lifetime, causing uncontrolled cell growth. However, the
nature and precise genomic locations of those changes, and how they
work to promote cancer, are largely unknown.
Harnessing the latest tools and technologies, a consortium of
researchers came together to characterize the complete sets of DNA, or
genomes, derived from tumors of nearly 200 patients with lung
adenocarcinoma. The effort, known as the Tumor Sequencing Project (TSP),
involved decoding or sequencing the DNA of several hundred genes with
known or suspected ties to cancer.
In addition, the scientists scanned tumor genomes to reveal chunks of
DNA that are either missing or present in excess copies. Scanning the
tumor genomes also allowed them to identify abnormally active as well as
These techniques, known as DNA copy number analysis and gene
expression analysis respectively, together with advanced computational
methods, helped provide a detailed view of the genomic landscape of lung
"Integrative approaches like these allow us to more clearly pinpoint
important genes than a single method alone would," said Meyerson.
As a result of this work, the researchers identified more than 1,000
genetic alterations, the majority of which had not been previously
described. While some of these mutations reflect genes already linked to
lung adenocarcinoma, a substantial number signify new discoveries.
For example, the NF1, ATM, RB1 and APC
genes, which have not before been associated with lung cancer, were
mutated in a significant portion of the lung tumors analyzed.
Interestingly, these genes have been implicated in other tumor types,
suggesting roles in multiple forms of cancer.
The consortium also unearthed genetic ties to a critical class of
genes known as tyrosine kinases. Kinases act as molecular switches —
when flipped on, they can promote cell growth — and are considered
important candidates in the search for new cancer drugs. In lung tumors,
the researchers uncovered mutations that cluster in several groups of
related tyrosine kinase genes, including the EGF, EPH, FGF, NTRK, and VEGF receptor gene families.
Beyond revealing abnormalities within individual genes, the
researchers uncovered extraordinary connections among them. By
integrating DNA sequencing, gene expression, and DNA copy number data,
they discovered that genetic aberrations are often localized to groups
of genes that function together, relaying information from one part of
the cell to another. All told, there are about 200 of these molecular
circuits or "signaling pathways" that operate in human cells — far fewer
than the roughly 20,000 genes.
"One of the key findings from our study is that some of the newly
discovered genes and pathways that are mutated in lung cancer are also
known to be defective in other cancers," said Meyerson. "That gives us
hope that targeted therapies could be used across multiple cancer
Among the broken pathways identified are the MAPK, Wnt, p53, and mTOR
pathways. Strikingly, the MAPK pathway was altered in roughly 70
percent of the tumors analyzed, suggesting a broad role in the disease.
In addition, the p53 and mTOR pathways were affected in roughly one-half
and one third of the tumors, respectively.
The TSP was first launched as a pilot project to investigate how
various genomic technologies could be effectively applied and integrated
to reveal the molecular underpinnings of lung adenocarcinoma. Together
with related efforts, including The Cancer Genome Atlas (TCGA), the
results of the Nature paper provide a critical foundation to
enhance future genomic work in lung adenocarcinoma and initiate
comprehensive genomic mapping for other common cancers.
The research was funded in part by National Human Genome Research
Institute. The study's first authors were Li Ding, PhD, Washington
University, St. Louis; Gad Getz, PhD, the Broad Institute; and David
Wheeler, PhD, Baylor College of Medicine. Other authors were based at
Dana-Farber and Brigham and Women's Hospital, in Boston; the Broad
Institute; Memorial Sloan-Kettering Cancer Center, New York; the
University of Cologne, Germany; the University of Michigan, Ann Arbor;
and M.D. Anderson Cancer Center, Houston.
Dana-Farber Cancer Institute (www.dana-farber.org)
is a principal teaching affiliate of the Harvard Medical School and is
among the leading cancer research and care centers in the United States.
It is a founding member of the Dana-Farber/Harvard Cancer Center
(DF/HCC), designated a comprehensive cancer center by the National
The Broad Institute of MIT and Harvard
was founded in 2003 to bring the power of genomics to biomedicine. It
pursues this mission by empowering creative scientists to construct new
and robust tools for genomic medicine, to make them accessible to the
global scientific community, and to apply them to the understanding and
treatment of disease.
The Institute is a research collaboration that involves faculty,
professional staff and students from throughout the MIT and Harvard
academic and medical communities. It is jointly governed by the two
Organized around Scientific Programs and Scientific Platforms, the
unique structure of the Broad Institute enables scientists to
collaborate on transformative projects across many scientific and